Johnson A P
Antibiotic Reference Laboratory, Central Public Health Laboratory, Colindale, London, UK.
J Hosp Infect. 1998 Sep;40(1):17-26. doi: 10.1016/s0195-6701(98)90020-2.
The resistance of bacteria to antibiotics, particularly those used for first-line therapy, is an increasing cause for concern. In the UK, the prevalence of resistance to methicillin and mupirocin in Staphylococcus aureus, and to penicillin and macrolides in Streptococcus pneumoniae, appear to be increasing. There has also been an increase in the number of hospitals where glycopeptide-resistant enterococci are known to have been isolated. The increases in methicillin-resistant S. aureus and glycopeptide-resistant enterococci are due, in part, to the inter-hospital spread of epidemic strains. Although new quinolones and streptogramins with activity against Gram-positive bacteria (including strains resistant to currently available agents) are under development, there is no reason to believe that resistance to these agents will not emerge. The control of resistance in Gram-positive bacteria will require a multi-faceted approach, including continued and improved surveillance, a reduction in the unnecessary use of antibiotics, and the application of other strategies such as vaccination.
细菌对抗生素,尤其是用于一线治疗的抗生素的耐药性,日益引起人们的关注。在英国,金黄色葡萄球菌对甲氧西林和莫匹罗星的耐药率,以及肺炎链球菌对青霉素和大环内酯类的耐药率似乎都在上升。已知分离出耐糖肽肠球菌的医院数量也有所增加。耐甲氧西林金黄色葡萄球菌和耐糖肽肠球菌数量的增加,部分原因是流行菌株在医院间传播。尽管正在研发对革兰氏阳性菌(包括对现有药物耐药的菌株)有活性的新型喹诺酮类和链阳菌素类药物,但没有理由相信不会出现对这些药物的耐药性。控制革兰氏阳性菌的耐药性需要多方面的方法,包括持续和改进监测、减少抗生素的不必要使用,以及应用其他策略,如接种疫苗。